{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:44:41Z","timestamp":1776721481391,"version":"3.51.2"},"reference-count":9,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Objetivo: Evaluar los cambios en las puntuaciones del Cuestionario de Nijmegen (CN) en pacientes con asma grave que reciben dupilumab y su relaci\u00f3n con el control de la enfermedad.\nM\u00e9todos: Estudio retrospectivo llevado a cabo en pacientes con asma grave, tratados con dupilumab. Se recopilaron datos epidemiol\u00f3gicos y cl\u00ednicos, as\u00ed como los resultados de los cuestionarios CN, Test de Control del Asma (TCA) y Cuestionario de Calidad de Vida en Asma (AQLQ), evaluando los cambios tras un a\u00f1o de tratamiento.\nResultados: Se incluyeron 18 pacientes (12 hombres y 6 mujeres), con mediana de edad de 54 a\u00f1os (rango: 27-67 a\u00f1os). La mediana del CN al inicio del tratamiento con dupilumab fue de 15.5 puntos (rango: 1-34) y a los 12 meses de 7 puntos (rango: 0-35). Antes del tratamiento, 5 (27.77%) pacientes reportaron una puntuaci\u00f3n superior a 23 puntos del CN, compatible con s\u00edndrome de hiperventilaci\u00f3n (SHV). La mediana de la puntuaci\u00f3n ACT fue de 19 (10-24) y en el control a los 12 meses fue de 23 (12-25). La mediana de la puntuaci\u00f3n AQLQ fue de 5 puntos (3-7) al inicio del tratamiento con dupilumab y de 6.08 puntos (3.50-7) luego de 12 meses de tratamiento. Se informaron cambios en las puntuaciones NQ despu\u00e9s de 12 meses de tratamiento con dupilumab, independientemente de las puntuaciones iniciales del cuestionario.\nConclusi\u00f3n: La incorporaci\u00f3n del Cuestionario de Nijmegen en la evaluaci\u00f3n de la respuesta al tratamiento con biol\u00f3gicos en pacientes con asma grave puede proporcionar informaci\u00f3n adicional para su seguimiento. El tratamiento adecuado de las comorbilidades, incluido el s\u00edndrome de hiperventilaci\u00f3n (SHV), es decisivo para optimizar los desenlaces en el control del asma.\nPalabras clave: Cuestionario de nijmegen; Cuestionario de calidad de vida en asma; Asma grave; Dupilumab; S\u00edndrome de hiperventilaci\u00f3n.<\/jats:p>","DOI":"10.29262\/ram.v72i4.1478","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:26:20Z","timestamp":1767828380000},"page":"271-275","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Changes in the Nijmegen Questionnaire in severe asthma patients treated with dupilumab Cambios en el Cuestionario de Nijmegen en pacientes con asma grave que reciben dupilumab &lt;\/b&gt;","&lt;b&gt;Cambios en el Cuestionario de Nijmegen en pacientes con asma grave que reciben dupilumab &lt;\/b&gt;"],"prefix":"10.29262","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9580-3138","authenticated-orcid":false,"given":"Isamar Carolina","family":"De Agrela-Mendes","sequence":"first","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Correa-Borit","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Lopez-Carrasco","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela Carmen","family":"Ifrim","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Turiel-Gomez","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"De Las Vecillas","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Quirce","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Dominguez-Ortega","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"65197","doi-asserted-by":"crossref","unstructured":"1. Howell JB. The hyperventilation syndrome: a syndrome under threat?. Thorax 1997; 52 (Suppl 3): S30-S34. doi: 10.1136\/thx.52.2008.s30","DOI":"10.1136\/thx.52.2008.S30"},{"key":"65198","doi-asserted-by":"crossref","unstructured":"2. Morgan MD. Dysfunctional breathing in asthma: is it common, identifiable and correctable?. Thorax 2002; 57 (Suppl 2): II31-II35.","DOI":"10.1136\/thorax.57.suppl_2.ii31"},{"key":"65199","doi-asserted-by":"crossref","unstructured":"3. Boulding R, Stacey R, Niven R, Fowler SJ. Dysfunctional breathing: a review of the literature and proposal for classification. Eur Respir Rev 2016; 25 (141): 287-294. doi: 10.1183\/16000617.0088-2015","DOI":"10.1183\/16000617.0088-2015"},{"key":"65200","doi-asserted-by":"crossref","unstructured":"4. Van Dixhoorn J, Duivenvoorden HJ. Efficacy of Nijmegen Questionnaire in recognition of the hyperventilation syndrome. J Psychosom Res 1985; 29 (2): 199-206. doi: 10.1016\/0022-3999(85)90042-x","DOI":"10.1016\/0022-3999(85)90042-X"},{"key":"65201","doi-asserted-by":"crossref","unstructured":"5. Thomas M, McKinley RK, Freeman E, Foy C, Price D. The prevalence of dysfunctional breathing in adults in the community with and without asthma. Prim Care Respir J 2005; 14 (2): 78-82. doi: 10.1016\/j.pcrj.2004.10.007","DOI":"10.1016\/j.pcrj.2004.10.007"},{"key":"65202","doi-asserted-by":"crossref","unstructured":"6. Grammatopoulou EP, Skordilis EK, Georgoudis G, et al. Hyperventilation in asthma: a validation study of the Nijmegen Questionnaire--NQ. J Asthma 2014; 51 (8): 839-846. doi: 10.3109\/02770903.2014.922190","DOI":"10.3109\/02770903.2014.922190"},{"key":"65203","doi-asserted-by":"crossref","unstructured":"7. Thomas M, Bruton A, Ainsworth B. Use of the Nijmegen Questionnaire in asthma. ERJ Open Res 2015; 1 (1): 00033-2015. doi: 10.1183\/23120541.00033-2015","DOI":"10.1183\/23120541.00033-2015"},{"key":"65204","doi-asserted-by":"crossref","unstructured":"8. Hekking PP, Amelink M, Wener RR, Bouvy ML, et al. Comorbidities in Difficult-to-Control Asthma. J Allergy Clin Immunol Pract 2018; 6 (1): 108-113. doi: 10.1016\/j.jaip.2017.06.008","DOI":"10.1016\/j.jaip.2017.06.008"},{"key":"65205","doi-asserted-by":"crossref","unstructured":"9. Hagman C, Janson C, Emtner M. Breathing retraining - a five-year follow-up of patients with dysfunctional breathing. Respir Med 2011; 105 (8): 1153-1159. doi: 10.1016\/j.rmed.2011.03.006","DOI":"10.1016\/j.rmed.2011.03.006"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1478\/2786","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1478\/2809","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1478\/2786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:56:43Z","timestamp":1776718603000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":9,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,19]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v72i4.1478","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"value":"2448-9190","type":"electronic"},{"value":"0002-5151","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}